Standout Papers
- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma (2016)
- B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches (2020)
- GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review (2024)
- Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022)
Immediate Impact
1 by Nobel laureates 7 from Science/Nature 62 standout
Citing Papers
Ultrasound-Based Micro-/Nanosystems for Biomedical Applications
2024 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Works of Ajai Chari being referenced
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
2022 Standout
Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
2020
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Ajai Chari | 3301 | 2587 | 2530 | 215 | 4.5k | |
| Peter M. Voorhees | 2816 | 3201 | 2660 | 170 | 5.1k | |
| Katja Weisel | 4153 | 3156 | 2910 | 329 | 5.5k | |
| Nizar J. Bahlis | 4063 | 3652 | 2693 | 348 | 5.7k | |
| Martin Kaiser | 2829 | 2894 | 1923 | 203 | 4.6k | |
| Nina Shah | 2067 | 1611 | 2410 | 258 | 3.9k | |
| Andrzej Jakubowiak | 3991 | 4056 | 2988 | 257 | 6.1k | |
| Luciano J. Costa | 3073 | 1849 | 2326 | 252 | 4.6k | |
| Ajay K. Nooka | 3399 | 2817 | 3302 | 273 | 5.8k | |
| Natalie S. Callander | 3853 | 3083 | 2709 | 199 | 5.7k | |
| Jacob P. Laubach | 3845 | 3817 | 2622 | 229 | 5.9k |
All Works
Login with ORCID to disown or claim papers
Loading papers...